Retatrutide and Diabetes: Impact on Blood Sugar and Glycemic Control

How Retatrutide Affects Blood Sugar

Retatrutide improves blood sugar control through three mechanisms. The GLP-1 component enhances glucose-dependent insulin secretion — the pancreas releases more insulin only when blood sugar is high, reducing the risk of hypoglycemia. The GIP component improves insulin sensitivity in peripheral tissues, meaning the body’s cells respond better to the insulin that is produced. The glucagon component, somewhat counterintuitively, also contributes to glycemic control by promoting fat oxidation and reducing the need for glucose as a fuel source. Together, these mechanisms produced significant improvements in glycemic markers in the clinical trials.

Clinical Data in Diabetic Populations

The TRIUMPH-2 and TRIUMPH-3 trials are specifically designed to evaluate retatrutide in people with type 2 diabetes. These trials have not yet reported as of May 2026, but the Phase 2 data included participants with prediabetes and showed significant improvements in HbA1c and fasting glucose. In the Phase 2 trial published in the New England Journal of Medicine in 2023, retatrutide reduced HbA1c by 1.5-2.0 percentage points in participants with elevated baseline values. This is comparable to tirzepatide and superior to semaglutide in cross-trial comparisons.

Retatrutide for Type 1 Diabetes

Retatrutide has not been studied in type 1 diabetes. The mechanism carries theoretical risks for type 1 patients, particularly the glucagon receptor activation, which could potentially increase the risk of diabetic ketoacidosis by promoting lipolysis and ketone production. GLP-1 drugs are occasionally used off-label in type 1 diabetes to improve glycemic control and reduce insulin requirements, but this should only be done under close medical supervision. No recommendation can be made for retatrutide use in type 1 diabetes without dedicated clinical data.